Why the study?
Neuropsychiatric medications can improve cardiovascular disease prognosis but may also cause cardiovascular side effects, making administration challenging.
What are the cardiovascular side effects of neuropsychiatric medications in patients with cardiovascular diseases?
What are the cardiovascular side effects of neuropsychiatric medications in patients with cardiovascular diseases?
This review highlights the double-edged sword relationship between neuropsychiatric medications and cardiovascular diseases, emphasizing the need to monitor for cardiovascular side effects.
Answers are grounded in this paper and cite their sources.
May warrant CV monitoring with neuropsychiatric meds; leaves open need for prospective trials in CVD populations.
Les maladies neuropsychiatriques ont une incidence croissante et prsentent un risque plus lev de morbidit et de mortalit prmature dans la population gnrale. De plus, les maladies cardiovasculaires se caractrisent par la prvalence la plus leve dans la population et constituent une cause majeure de morbidit prcoce, en particulier par la survenue d'vnements ischmiques coronariens. Rcemment, l'implication des maladies neuropsychiatriques dans la dtermination des maladies cardiovasculaires a t dmontre. D'une part, le traitement de ces maladies peut amliorer le pronostic des maladies cardiovasculaires, mais d'autre part l'iatrognse peut jouer un rle trs important dans leur dterminisme. C'est pourquoi l'administration des mdicaments neuropsychiatriques peut tre trs difficile pour les patients atteints de maladies cardiovasculaires en raison de leurs effets secondaires. Dans cet article, nous avons l'intention de prsenter le lien entre le traitement antidpresseur et antipsychotique et le systme cardiovasculaire, afin de rsumer les informations actuelles sur les divers effets ABSTRACT Neuropsychiatric diseases have a rising incidence and cause a significantly higher risk of morbidity and premature mortality in the general population. Also, cardiovascular diseases (CVDs) are characterized by the highest prevalence in the population and are a major cause of early morbidity, especially through the occurrence of coronary ischemic events. Recently, it has been demonstrated the involvement of neuropsychiatric diseases in the aetiology of CVDs. On the one hand, the treatment of these diseases can improve the prognosis of CVD, but on the other hand iatrogenesis may play a very important role in their determinism. Administrating neuropsychiatric medication (NPM) can be very challenging for patients with CVD because of their cardiovascular side effects (CVSEs). NPM and CVDs have a double edged-sword relationship. The purpose of this review is to present the link between the treatment with antidepressants and antipsychotics and the cardiovascular system, and to summarize the current information of the various CVSEs of NPM.
No takes yet. Share an insight, caveat, or question.
APETREI-CORDUNEANU et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: